| Abstrakt: |
Purpose: In order to examine the parameters of surgical operation between intravitreal bevacizumab and ranibizumab as adjuvant therapy before pars plana vitrectomy in proliferative diabetic retinopathy. Patients & methods: A randomized clinical study on 68 eyes, the patients are classified into two groups, group A (n = 34), and group B (n =34), both groups injected by anti-vascular endothelial growth factor before vitrectomy operation, group A injected by Bevacizumab and group B injected by Ranibizumab, the duration between injection and the operation was 3-6 days, the basic data of each patient include vision, type of DM, duration of DM, level of HbA1c, during the operation we record the following parameters diathermy application number, breaks, bleeding, bottle height, and type of tamponade. Results: The mean BCVA was improved from base line to post- operative in both groups without statistically difference between the groups p value =0.231, diathermy application was one application in 30.3% in group A and 32.4% in group B, and two applications in 15.2% in group A and 2.9% in group B. break was one break in 23.5% in group A and 20.6% in group B. two breaks in 2.9% in each group. Bleeding was in 16 cases in group A and 17 cases in group B. tamponade was silicon in 58.8% in group A and 52.9% in group B, fluid tamponade was 38.3% in group A and 44.2% in group B, air tamponade was one case in each group. without statistical difference between groups. Conclusion: When administered preoperatively during a diabetic vitrectomy procedure, there is no difference between bevacizumab and ranibizumab. [ABSTRACT FROM AUTHOR] |
